Journal
CANCER LETTERS
Volume 438, Issue -, Pages 17-23Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2018.08.028
Keywords
Cancer immunogenic cell death; ICD inducers; Anti-tumor immunity
Categories
Funding
- National Natural Science Foundation of China [81502621, 81502088]
- China Postdoctoral Science Special Foundation [2017M5654]
- Jiangsu Provincial Key Research and Development Special Fund [BE2015666]
- Jiangsu Innovative team leading talent fund [CXTDC2016006, QNRC2016446]
- Jiangsu six high peak talent fund [WSW-205]
- Jiangsu 333 talent fund [BRA2016140]
- Medical clinical science and technology development fund of Jiangsu University [JLY20140010]
- Priority Academic Program Development of Jiangsu Higher Education Institutions
Ask authors/readers for more resources
The traditional view holds that apoptosis is non-immunogenic and does not induce an inflammatory response. However, recent studies have suggested that certain chemotherapeutic drugs that induce tumor cell apoptosis can induce immunogenic cell death (ICD) in cancer cells. This process is characterized by not only up-regulation of a series of signaling molecules in cancer cells, including expose of calreticulin (CRT), secretion of adenosine triphosphate (ATP) and release of high mobility group box 1 (HMGB1). In this review, we summarize recent progress in identifying and classifying ICD inducers; concepts and molecular mechanisms of ICD; and the impact and potential applications of ICD in clinical studies. We also discuss the contributions of ICD inducers in combination with other anticancer drugs in clinical applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available